Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma

Neoplasia

Volumn 13, Issue 1, 2011, Pages 12-22

  Ou, Wen Bin ^a,b   Hubert, Christopher ^a,b   Corson, Joseph M ^a,b   Bueno, Raphael ^a   Flynn, Daniel L ^c   Sugarbaker, David J ^a   Fletcher, Jonathan A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Department of Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; CASPASE 3; CASPASE 7; CHAPERONE; DP 3975; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEFITINIB; HEAT SHOCK PROTEIN 90; PROTEIN AXL; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; S6 KINASE; SCATTER FACTOR RECEPTOR; TANESPIMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MESOTHELIOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 78650972238     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101156     Document Type: Article

References (42)

1. Craighead JE (1987). Current pathogenetic concepts of diffuse malignant mesothelioma. Hum Pathol 18, 544-557.
2. Sahin AA, Coplu L, Selcuk ZT, Eryilmaz M, Emri S, Akhan O, and Baris YI (1993). Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: CT findings in 84 patients. AJR Am J Roentgenol 161, 533-537.
3. Carbone M, Pass HI, Miele L, and Bocchetta M (2003). New developments about the association of SV40 with human mesothelioma. Oncogene 22, 5173-5180.
4. Peto J, Hodgson JT, Matthews FE, and Jones JR (1995). Continuing increase in mesothelioma mortality in Britain. Lancet 345, 535-539.
5. Pache JC, Janssen YM, Walsh ES, Quinlan TR, Zanella CL, Low RB, Taatjes DJ, and Mossman BT (1998). Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. Am J Pathol 152, 333-340.
6. Zanella CL, Posada J, Tritton TR, and Mossman BT (1996). Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res 56, 5334-5338.
7. Janne PA, Taffaro ML, Salgia R, and Johnson BE (2002). Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 62, 5242-5247.
8. Tolnay E, Kuhnen C, Wiethege T, Konig JE, Voss B, and Muller KM (1998). Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 124, 291-296.
9. Klominek J, Baskin B, Liu Z, and Hauzenberger D (1998). Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor. Int J Cancer 76, 240-249.
10. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, et al. (2006). Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66, 352-361.
11. Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, and Janne PA (2005). Inhibition of the met receptor in mesothelioma. Clin Cancer Res 11, 8122-8130.
12. Cacciotti P, Libener R, Betta P, Martini F, Porta C, Procopio A, Strizzi L, Penengo L, Tognon M, Mutti L, et al. (2001). SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA 98, 12032-12037.
13. Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, and Gill PS (2005). Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res 11, 4305-4315.
14. Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, Watanabe Y, and Pass HI (1999). VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81, 54-61.
15. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, Puntoni R, Mutti L, and Procopio A (2001). Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193, 468-475.
16. Lee TC, Zhang Y, Aston C, Hintz R, Jagirdar J, Perle MA, Burt M, and Rom WN (1993). Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res 53, 2858-2864.
17. Pass HI, Mew DJ, Carbone M, Matthews WA, Donington JS, Baserga R, Walker CL, Resnicoff M, and Steinberg SM (1996). Inhibition of hamster mesothelioma tumorigenesis by an antisense expression plasmid to the insulin-like growth factor-1 receptor. Cancer Res 56, 4044-4048.
18. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, et al. (1998). Phase II study of receptorenhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16, 2659-2671.
19. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347, 472-480.
20. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, et al. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344, 1031-1037.
21. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500.
22. Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, Pottorf BJ, Nitz MD, Richards WG, Sugarbaker DJ, et al. (2005). Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 166, 1827-1840.
23. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, et al. (2001). KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61, 8118-8121.
24. Workman P (2004). Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 206, 149-157.
25. Gschwind A, Fischer OM, and Ullrich A (2004). The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4, 361-370.
26. Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D, Green MR, and Kindler HL (2005). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11, 2300-2304.
27. Mathy A, Baas P, Dalesio O, and van Zandwijk N (2005). Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 50, 83-86.
28. Harvey P, Clark IM, Jaurand MC, Warn RM, and Edwards DR (2000). Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 83, 1147-1153.
29. Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, et al. (2006). EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51, 207-215.
30. Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, et al. (2009). Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 30, 1097-1105.
31. Janssen JW, Schulz AS, Steenvoorden AC, Schmidberger M, Strehl S, Ambros PF, and Bartram CR (1991). A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 6, 2113-2120.
32. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R III, Le Beau MM, Earp HS, and Liu ET (1991). axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11, 5016-5031.
33. Sreedhar AS, Soti C, and Csermely P (2004). Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim Biophys Acta 1697, 233-242.
34. Sreedhar AS, Kalmar E, Csermely P, and Shen YF (2004). Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 562, 11-15.
35. Sharp S and Workman P (2006). Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 95, 323-348.
36. Isaacs JS, Xu W, and Neckers L (2003). Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3, 213-217.
37. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, Inukai A, Doyu M, and Sobue G (2005). 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 11, 1088-1095.
38. Csermely P, Schnaider T, Soti C, Prohaszka Z, and Nardai G (1998). The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 79, 129-168.
39. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, et al. (2006). Development of 17-allylamino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 103, 17408-17413.
40. Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT, Clement G, Yagui-Beltran A, Ray MR, Koizumi K, et al. (2008). Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol 3, 1089-1095.
41. Baldi A, Groeger AM, Esposito V, Cassandro R, Tonini G, Battista T, Di Marino MP, Vincenzi B, Santini M, Angelini A, et al. (2002). Expression of p21 in SV40 large Tantigen positive human pleural mesothelioma: relationship with survival. Thorax 57, 353-356.
42. Bongiovanni M, Cassoni P, De Giuli P, Viberti L, Cappia S, Ivaldi C, Chiusa L, and Bussolati G (2001). p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer 92, 1245-1250.